Superficial radiation therapy in peyronie's disease: An effective and well-tolerated therapy
- PMID: 30370354
- PMCID: PMC6200896
- DOI: 10.1016/j.adro.2018.07.009
Superficial radiation therapy in peyronie's disease: An effective and well-tolerated therapy
Abstract
Purpose: This study aimed to assess the safety, efficacy, and patient satisfaction of superficial radiation therapy in the treatment of Peyronie's disease (PD) in a retrospective analysis.
Methods and materials: We performed a retrospective analysis of 83 patients who underwent radiation therapy between 1999 and 2008 with 8 fractions of 4 Gy over a period of 6 months. With a mean follow-up time of 52 months, patients responded to a comprehensive questionnaire that covered patient characteristics, disease duration before radiation therapy, course of disease, treatment response, side effects, and patient satisfaction.
Results: After a mean follow-up time of 52 months, 78% of the treated patients reported that PD progression had stopped. Furthermore 47% of patients had a symptom regression. Only 7% of patients reported PD progression. The penile curvature was improved in 49% of patients, and plaque induration could be reduced in 42% of patients. Moreover, 71% of patients reported substantial pain relief, as measured by a visual analogue scale (1 = not satisfied; 10 = very satisfied). Treatment satisfaction was rated with a median of 8 in a visual analogue scale out of 10. Side effects included transient erythema in 38.6% of patients and 9.6% reported of transient or chronic dryness. No severe side effects were observed.
Conclusions: Radiation therapy for PD in the disease's early stages proved to be a safe and well-tolerated method with good results in pain relief, especially in patients aged <62 years. No serious adverse events or malign transformations are expected using doses up to 32 Gy.
Similar articles
-
Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.BJU Int. 2012 Jul;110(1):117-21. doi: 10.1111/j.1464-410X.2011.10733.x. Epub 2011 Dec 16. BJU Int. 2012. PMID: 22176734 Clinical Trial.
-
Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study.J Sex Med. 2015 Jan;12(1):248-58. doi: 10.1111/jsm.12731. Epub 2014 Nov 12. J Sex Med. 2015. PMID: 25388099 Clinical Trial.
-
Outcomes of RestoreX Penile Traction Therapy in Men With Peyronie's Disease: Results From Open Label and Follow-up Phases.J Sex Med. 2020 Dec;17(12):2462-2471. doi: 10.1016/j.jsxm.2020.10.003. Epub 2020 Nov 20. J Sex Med. 2020. PMID: 33223425 Clinical Trial.
-
Peyronie's disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men.Korean J Urol. 2015 Nov;56(11):775-80. doi: 10.4111/kju.2015.56.11.775. Epub 2015 Nov 4. Korean J Urol. 2015. PMID: 26568796 Free PMC article. Review.
-
Penile prosthesis implantation in the treatment of Peyronie's disease.Int J Impot Res. 1998 Jun;10(2):125-8. doi: 10.1038/sj.ijir.3900330. Int J Impot Res. 1998. PMID: 9647951 Review.
Cited by
-
Radiotherapy for non-cancer diseases: benefits and long-term risks.Int J Radiat Biol. 2024;100(4):505-526. doi: 10.1080/09553002.2023.2295966. Epub 2024 Jan 5. Int J Radiat Biol. 2024. PMID: 38180039 Free PMC article. Review.
-
Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Curr Urol Rep. 2021 Jan 8;22(2):6. doi: 10.1007/s11934-020-01024-8. Curr Urol Rep. 2021. PMID: 33420664 Review.
References
-
- Schwarzer U., Sommer F., Klotz T., Braun M., Reifenrath B., Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int. 2001;88:727–730. - PubMed
-
- Ji J., Tian Y., Zhu Y.Q., Zhang L.Y., Ji S.J., Huan J. Ionizing irradiation inhibits keloid fibroblast cell proliferation and induces premature cellular senescence. J Dermatol. 2015;42:56–63. - PubMed
LinkOut - more resources
Full Text Sources